Lung Health Life Expectancy and Recovery After Pulmonary Embolism By Angela Ryan Lee, MD Angela Ryan Lee, MD Dr. Angela Ryan Lee is board certified in cardiology and internal medicine. Her professional interests include preventive cardiology, medical journalism, and health policy. Learn about our editorial process Published on November 29, 2022 Medically reviewed by Reza Samad, MD Medically reviewed by Reza Samad, MD Reza Samad, MD, is a board-certified pulmonologist and assistant professor of medicine. Learn about our Medical Expert Board Print Table of Contents View All Table of Contents Does It Reduce Life Expectancy? Recovery Time During Recovery Ongoing Treatment Frequently Asked Questions Pulmonary embolism (PE) is a potentially life-threatening situation in which a blood clot becomes lodged in the blood vessels of the lungs. It can block blood flow to the lungs, leading to low oxygen levels, rapid heart rate, and in some cases, death. Survival after PE depends on several factors, including age, underlying medical conditions, and the size of the clot. After PE, mortality can range from 5–15% but may be higher or lower depending on the circumstances. Read on to learn more about factors affecting life expectancy and recovery after a PE. The Good Brigade / Getty Images Does a Pulmonary Embolism Reduce Life Expectancy? PE is a potentially life-threatening situation with variable effects on life expectancy. A large clot in the pulmonary arteries may strain the heart, lower oxygen levels, and ultimately lead to cardiovascular collapse and death. This is referred to as a massive PE. However, not all PEs are large or significant enough to even cause any symptoms. These PEs are considered low risk, and some PEs are even found incidentally on imaging performed for other reasons. PEs can be categorized in different ways, and management varies based on the following types: Provoked PE: A PE that has an identifiable risk factor, such as surgery, trauma, pregnancy, or hormonal contraception.Unprovoked PE: A PE in which no risk factor is identified.Massive PE: A PE causing low blood pressure and elevated heart rate.Sub-massive PE: A PE causing a strain on the heart, which may be identified on imaging tests and/or with labs.Low-risk PE: A PE without any effect on blood pressure or heart rate and without signs of heart strain Survival Rate In some studies, short-term (or 30-day) mortality rates with PE are as high as 18%. However, mortality rates vary based on multiple factors. Clinical scores have been developed to provide a prognosis and guide the management of PE. These incorporate underlying risk factors, vital signs, and certain markers present at the time of diagnosis. The Pulmonary Embolism Severity Index (PESI) is one such score that provides an estimate of 30-day mortality based on the following: Age and sex History of medical conditions like heart failure, cancer, and underlying lung disease Vital signs (blood pressure, heart rate, respiratory rate, and temperature) Oxygen saturation Altered mentation, such as the presence of confusion or coma PE Mortality Rates Based on Various Factors One large study in Alberta, Canada, found the following 5-year mortality rates that varied based on the underlying risk factors for PE:PE in presence of cancer: 61% 5-year mortalityProvoked PE: 20% 5-year mortalityUnprovoked PE: 15% 5-year mortalitySeparately, studies estimate 90-day mortality rates based on the severity of the PE as follows:Massive PE: 58.3% 90-day mortalitySub-massive PE: 15.1% 90-day mortalityLow-risk PE: <2% 90-day mortality Long-Term Symptoms and Complications Unfortunately, surviving a PE isn't the end of the story. Long-term complications can cause symptoms even years after a PE is diagnosed. Additionally, the risk of repeat blood clots may increase. Pulmonary Infarction When blood flow to the lungs is blocked by a PE, the lung tissue can die of starvation, from lack of oxygen and nutrients. This is known as pulmonary infarction. When a large enough portion of lung tissue is permanently damaged, shortness of breath and exercise intolerance can result. Supplemental oxygen may be necessary in some cases. CTEPH Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of PE that can cause chronic shortness of breath. CTEPH is a form of pulmonary hypertension, in which the pressure in the lung arteries is elevated due to blood clots and scarring. Surgery is the preferred treatment for CTEPH for those who are candidates. It is also managed via medication if a person isn't eligible for surgery. Lung transplant is for those who are not candidates for or who have failed surgery or medical treatments. Recurrent Blood Clots People who have experienced a PE may be at higher risk of another blood clot. The risk depends on the reason for the first blood clot. If cancer or an underlying blood clotting disorder is present, for example, the risk is higher. In some cases, lifelong blood thinning medication may be recommended. Factors That Affect Recovery Time Recovery after PE varies based on factors like underlying medical conditions and the reason for the blood clots in the lung. Knowing what to expect can help with coping during recovery and set you up for the best chance of success. The following factors can affect recovery time: Size of blood clot (massive, sub-massive, or low-risk)AgeUnderlying medical conditions, like heart failure, lung disease, smoking, or cancerBaseline health status What to Expect During Recovery If you are diagnosed with a PE, you may be monitored in the hospital for a few days and start taking a blood-thinning medication called an anticoagulant. In addition to blood thinners, you may need supplemental oxygen and pain medications temporarily. If the PE is very large or causing significant strain on the heart, your healthcare team may recommend a procedure to remove the clot (embolectomy) or deliver medication to break up the clot (thrombolysis). For those who can not take blood-thinning medications, the placement of a device called an IVC filter may be recommended. IVC filters prevent other clots from the leg or pelvic veins from traveling up to the lungs and causing more problems. Recovery at Home Not everyone with PE requires a hospital stay. If the PE is small and there are otherwise no risk factors, your healthcare team may consider it safe to send you home with blood thinning medication for recovery at home. When you are home from the hospital, you should continue the prescribed blood thinning medication without missing any doses. This medication doesn't break up the clot directly but helps prevent the clot from getting bigger while your body breaks down the clot over months. Normally, blood thinners are required for at least three months, often longer. Your healthcare team can help determine when or if it is safe to discontinue blood thinners. It's important to note that you may experience some physical deconditioning after PE. This may be related to the damage to the lungs themselves, but even the immobilization of staying in the hospital can quickly lead to weakness and fatigue. Returning to exercise under your healthcare provider's guidance may involve slowly getting back to exercise, starting with recumbent activity like a stationary bicycle and working your way up to your previous activity levels. It's important to keep as active as possible because immobility is a risk factor for blood clots. Lastly, age-appropriate cancer screening should be performed, particularly in unprovoked PE patients. And your healthcare team may recommend follow-up testing with lung imaging, heart imaging, and/or pulmonary function testing. Warning Signs If you have difficulty filling your blood thinner prescription, speak with your healthcare provider right away. If you notice worsening symptoms of shortness of breath, chest pain, and activity intolerance, seek medical attention promptly. Ongoing Treatment at a Glance You must address any underlying causes of blood clotting. Depending on the cause of the PE, you may be advised to remain on lifelong blood-thinning medication. These medications have a risk of bleeding, so it's important to discuss this risk with your healthcare provider and avoid any activities with a risk of head injury, such as contact sports. Summary The prognosis after a PE varies widely based on many factors. Age, underlying health conditions, and blood clot size are some predictors of mortality. Blood thinners are a cornerstone of therapy, and are typically recommended for at least three months, and sometimes indefinitely. Recovery can take weeks to months, though there are some complications that can lead to long-lasting symptoms. It's important to take medication as prescribed and stay as active as possible to prevent further blood clots. A Word From Verywell Experiencing a PE can be an extremely frightening experience, from the symptoms of shortness of breath, chest pain, and anxiety to hospitalization and various medical testing. Know that it is normal for recovery to take time, and your healthcare team will work with you on a treatment plan. Frequently Asked Questions What are the odds of full recovery after a pulmonary embolism? The chances of full recovery really depend on the individual circumstances, including whether there is an underlying condition (such as cancer) present and how much lung tissue was damaged. In low-risk PE that does not cause strain on the heart, full recovery is expected, and mortality rates are less than 2%. Learn More: Pulmonary Embolism Treatment How long does it take to recover from a blood clot in your lungs or heart? Recovery from a pulmonary embolism or blood clot in the heart can take months. You will need to be on blood-thinning medication for at least three months or longer to prevent the clot from getting bigger while your body breaks down the clot. Learn More: Coping With Pulmonary Embolism Can you have a second pulmonary embolism? Yes. In fact, if you've had one pulmonary embolism (PE), your chances of having a second one are higher. This is true particularly if your PE was considered "unprovoked," meaning no underlying cause was identified, or if you have a persistent risk factor, such as a clotting disorder. It's important to complete the treatment duration of blood-thinning medication to avoid enlargement of the clot or more blood clots. 17 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Barnes GD, Muzikansky A, Cameron S, et al. Comparison of 4 acute pulmonary embolism mortality risk scores in patients evaluated by pulmonary embolism response teams. JAMA Netw Open. 2020;3(8):e2010779. doi:10.1001/jamanetworkopen.2020.10779 Chiu V, O'Connell C. Management of the incidental pulmonary embolism. AJR Am J Roentgenol. 2017;208(3):485-488. doi:10.2214/AJR.16.17201 Gjonbrataj E, Kim JN, Gjonbrataj J, et al. Risk factors associated with provoked pulmonary embolism. Korean J Intern Med. 2017;32(1):95-101. doi:10.3904/kjim.2015.118 Senyei G, Fernandes T. Expert analysis: duration of anticoagulation post-PE: things to consider. American College of Cardiology. 2019 March 22. Published online. Sadeghi A, Brevetti GR, Kim S, et al. Acute massive pulmonary embolism: role of the cardiac surgeon. Tex Heart Inst J. 2005;32(3):430-433. Nguyen PC, Stevens H, Peter K, McFadyen JD. Submassive pulmonary embolism: current perspectives and future directions. JCM. 2021;10(15):3383. doi:10.3390/jcm10153383. Aggarwal V, Nicolais CD, Lee A, Riyaz B. Expert Analysis: acute management of pulmonary embolism. 2017 Oct 24. American College of Cardiology. Published Online. Surov A, Akritidou M, Bach AG, et al. A new index for the prediction of 30-day mortality in patients with pulmonary embolism: the Pulmonary Embolism Mortality Score (PEMS). Angiology. 2021 Sep;72(8):787-793. doi:10.1177/0003319721993346 Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172(8):1041-1046. doi:10.1164/rccm.200506-862OC University of California at San Diego Health. Deep venous thrombosis and pulmonary embolism. Kaptein FHJ, Kroft LJM, Hammerschlag G, et al. Pulmonary infarction in acute pulmonary embolism. Thromb Res. 2021;202:162-169. doi:10.1016/j.thromres.2021.03.022 Chest Foundation. Chronic thromboembolic pulmonary hypertension. Áinle FN, Kevane B. Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? Blood Adv. 2020 Nov 10;4(21):5595-5606. doi:10.1182/bloodadvances.2020002268 Rivera-Lebron B, McDaniel M, Ahrar K, et al; PERT Consortium. Diagnosis, treatment and follow up of acute pulmonary embolism: consensus practice from the PERT Consortium. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619853037. doi:10.1177/1076029619853037 Kelkar AH, Rajasekhar A. Inferior vena cava filters: a framework for evidence-based use. Hematology Am Soc Hematol Educ Program. 2020;2020(1):619-628. doi:10.1182/hematology.2020000149 Lutsey PL, Walker RF, MacLehose RF, et al. Inpatient versus outpatient acute venous thromboembolism management: trends and postacute healthcare utilization from 2011 to 2018. J Am Heart Assoc. 2021 Oct 19;10(20):e020428. doi:10.1161/JAHA.120.020428 Boon GJAM, Bogaard HJ, Klok FA. Essential aspects of the follow-up after acute pulmonary embolism: an illustrated review. Res Pract Thromb Haemost. 2020;4(6):958-968. doi:10.1002/rth2.12404 By Angela Ryan Lee, MD Angela Ryan Lee, MD, is board-certified in cardiovascular diseases and internal medicine. She is a fellow of the American College of Cardiology and holds board certifications from the American Society of Nuclear Cardiology and the National Board of Echocardiography. She completed undergraduate studies at the University of Virginia with a B.S. in Biology, medical school at Jefferson Medical College, and internal medicine residency and cardiovascular diseases fellowship at the George Washington University Hospital. Her professional interests include preventive cardiology, medical journalism, and health policy. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit